BioSpace News Archive

The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD students conducting research in stem cell biology, biophysics, gene editing, cell therapy, and bioproduction engineering.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAQ™ Hepatitis C (“HCV”) Viral Load Kit as an in vitro diagnostic (“IVD”).

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022.

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 28, 2022.

Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson to chief executive officer.

The global companion diagnostics market is expected to reach the value of US$ 9.30 Bn by the end of 2030 and it is estimated to expand at a CAGR of 9% from 2021 to 2030.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company is adding a new asset to its pipeline portfolio, HT-TBI, which is based on scientific research performed by Hoth.

The global medical devices outsourcing market size was valued at US$ 102.6 Bn in 2020 and is expected to reach valuation US$ 232.8 Bn by 2030 with a CAGR of 11.2% from 2021 to 2030.

The global population health management market is expected to reach valuation US$ 86.9 Bn by 2030 and is estimated to expand at a CAGR of 15.9% from 2021 to 2030

Heat Biologics, Inc. announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company’s evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company’s new biodefense capabilities.